×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Beacon Therapeutics unveils interim results for AGTC-501
Pharmaceutical Technology
AGTC-501, like Luxturna, is a gene therapy. Despite this, it stands out by offering an alternative mechanism of action. AGTC-501 is an X-linked...
2 months ago
Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X ...
PR Newswire
AGTC-501 was generally safe and well-tolerated and showed robust improvements in visual function at the 12-month analysis; Pivotal Phase 2/3...
2 months ago
AgTC's Friedmann hails FMC rule implementing Ocean Shipping Reform Act
American Journal of Transportation
The mandate of this new rule, “prohibiting carriers from imposing Detention & Demurrage charges on parties with whom they have no contractual...
2 months ago
FMC should guard against carrier ‘profit center’ from Red Sea surcharges: AgTC chief
Journal of Commerce
With ocean carriers rushing to the FMC to seek waivers of the 30-day notice period required to implement surcharges linked to the Red Sea...
4 months ago
Promising Gene Therapy for X-linked Retinitis Pigmentosa: Beacon Therapeutics' AGTC-501 Shows Positive Results
Medriva
Beacon Therapeutics' AGTC-501 expresses the full-length RPGR protein. This makes it an ideal candidate as a potential treatment for XLRP as it...
2 months ago
Beacon's AGTC-501 to challenge Spark's Luxturna in retinitis market
The Pharma Letter
Beacon's AGTC-501 to challenge Spark's Luxturna in retinitis market ... Beacon Therapeutics' gene therapy AGTC-501 (laruparetigene zovaparvovec)...
2 months ago
Beacon of Light: Retinal Gene Therapy Developer Launches with $120M
Genetic Engineering and Biotechnology News
A gene therapy developer focused on treating retinal diseases is being launched with £96 million (about $120 million) in Series A financing...
10 months ago
Syncona launches new gene therapy company Beacon Therapeutics
biopharma-reporter.com
Syncona has launched Beacon Therapeutics, a new ophthalmic gene therapy company with a purpose to restore and improve the vision of patients...
10 months ago
AGTC-601 gene therapy shows efficacy and safety in model of FTD with granulin mutations
BioWorld MedTech
Researchers from Applied Genetic Technologies Corp. have reported preclinical data for AGTC-601, a novel AAVrh10-granulin (GRN) gene therapy...
11 months ago
Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022
Yahoo Finance
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC),...
17 months ago